**Core Concept**
Aspirin is an antiplatelet agent that exerts its effects by inhibiting the production of thromboxane A2, a potent platelet activator. This mechanism is crucial in preventing recurrent myocardial infarctions in patients who have undergone coronary artery bypass grafting.

**Why the Correct Answer is Right**
Aspirin exerts its effects through the inhibition of cyclooxygenase-1 (COX-1), an enzyme involved in the synthesis of thromboxane A2 from arachidonic acid. Thromboxane A2 is a powerful platelet aggregator that promotes platelet adhesion and aggregation, leading to thrombus formation. By inhibiting COX-1, aspirin reduces the production of thromboxane A2, thereby preventing platelet activation and aggregation.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because aspirin's mechanism of action is not directly related to the inhibition of prostaglandin synthesis, although prostaglandins are also produced through the COX pathway.
**Option B:** This option is incorrect because while aspirin does affect the COX pathway, it is not primarily involved in the synthesis of prostacyclin, which is an antiplatelet agent produced by endothelial cells.
**Option C:** This option is incorrect because the synthesis of leukotrienes is not directly affected by aspirin's mechanism of action.

**Clinical Pearl / High-Yield Fact**
Aspirin's antiplatelet effects are not limited to coronary artery disease; it is also used in the prevention of stroke and peripheral artery disease. The antiplatelet effects of aspirin are dose-dependent, with higher doses required to achieve optimal efficacy.

**Correct Answer:** D. thromboxane A2